title: Stereotactic radiosurgery using the gamma knife for acoustic neuromas.
abstract: OBJECTIVE
  To assess the efficacy and toxicity of stereotactic radiosurgery using the gamma knife for acoustic neuromas.
  
  
  METHODS
  Between January 1990 and January 1993, 36 patients with acoustic neuromas were treated with stereotactic radiosurgery using the gamma knife. The median maximum tumor diameter was 21 mm (range: 6-32 mm). Tumor volumes encompassed within the prescribed isodose line varied from 266 to 8,667 mm3 (median: 3,135 mm3). Tumors < or = 20 mm in maximum diameter received a dose of 20 Gy to the margin, tumors between 21 and 30 mm received 18 Gy, and tumors > 30 mm received 16 Gy. The dose was prescribed to the 50% isodose line in 31 patients and to the 45%, 55%, 60%, 70%, and 80% isodose line in one patient each. The median number of isocenters per tumor was 5 (range: 1-12).
  
  
  RESULTS
  At a median follow-up of 16 months (range: 2.5-36 months), all patients were alive. Thirty-five patients had follow-up imaging studies. Nine tumors (26%) were smaller, and 26 tumors (74%) were unchanged. No tumor had progressed. The 1- and 2-year actuarial incidences of facial neuropathy were 52.2% and 66.5%, respectively. The 1- and 2-year actuarial incidences of trigeminal neuropathy were 33.7% and 58.9%, respectively. The 1- and 2-year actuarial incidence of facial or trigeminal neuropathy (or both) was 60.8% and 81.7%, respectively. Multivariate analysis revealed that the following were associated with the time of onset or worsening of facial weakness or trigeminal neuropathy: (a) patients < age 65 years, (b) dose to the tumor margin, (c) maximum tumor diameter > or = 21 mm, (d) use of the 18 mm collimator, and (e) use of > five isocenters. The 1- and 2-year actuarial rates of preservation of useful hearing (Gardner-Robertson class I or II) were 100% and 41.7% +/- 17.3, respectively.
  
  
  CONCLUSIONS
  Stereotactic radiosurgery using the gamma knife provides short-term control of acoustic neuromas when a dose of 16 to 20 Gy to the tumor margin is used. Preservation of useful hearing can be accomplished in a significant proportion of patients.
authors.affiliation: Mayo Clinic, Division of Radiation Oncology, Rochester, MN 55905, USA.
authors.forename: R L
authors.initials: RL
authors.lastname: Foote
authors.forename: R J
authors.initials: RJ
authors.lastname: Coffey
authors.forename: J W
authors.initials: JW
authors.lastname: Swanson
authors.forename: S G
authors.initials: SG
authors.lastname: Harner
authors.forename: C W
authors.initials: CW
authors.lastname: Beatty
authors.forename: R W
authors.initials: RW
authors.lastname: Kline
authors.forename: L N
authors.initials: LN
authors.lastname: Stevens
authors.forename: T C
authors.initials: TC
authors.lastname: Hu
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D005158:Facial Paralysis / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009464:Neuroma, Acoustic / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects / Q000295:instrumentation*; D014277:Trigeminal Neuralgia / Q000453:epidemiology / Q000209:etiology*